Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with docetaxel or nab-paclitaxel as second-line treatment for advanced non-small cell lung cancer
ChiCTR1900028430Phase 2Not yet recruiting
- Sponsor
- Ganyu District People's Hospital of Lianyungang City
- Start
- Dec 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, docetaxel and paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Ganyu District People's Hospital of Lianyungang City. Primary endpoint: Tumor size. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
anlotinibdocetaxelpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900028430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028430.